In the last 20 years, the world has witnessed a rapid rise in diabetes and the complications associated with it (1). Cardiovascular diseases (CVD) are the most common complications of diabetes and are responsible for high mortality in diabetics (2). Therefore, the current challenge in diabetes management is to reduce such complications (3). In this aspect, the ADVANCE trial has already established the CV safety of sulfonylureas (4).
Moreover, the favorable cardiovascular effects of Glimepiride has also been proven in some studies (5). In addition to this, the recent results from CAROLINA trial have also favored the CV safety of Glimepiride (6). Therefore the question arises, " Does Glimepiride Require A CVOT ?" Sanofi and Docplexus have organized an interactive webinar on 4th June at 2:30 pm for the same question. In this…
